

Yoshikazu Inoue

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9093665/yoshikazu-inoue-publications-by-citations.pdf>
Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126 papers	12,821 citations	42 h-index	113 g-index
134 ext. papers	17,225 ext. citations	9.7 avg, IF	5.68 L-index

#	Paper	IF	Citations
126	Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. <i>New England Journal of Medicine</i> , 2014 , 370, 2071-82	59.2	2337
125	An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 733-48	10.2	2176
124	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, e44-e68	10.2	1426
123	Efficacy and safety of sirolimus in lymphangioleiomyomatosis. <i>New England Journal of Medicine</i> , 2011 , 364, 1595-606	59.2	724
122	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. <i>New England Journal of Medicine</i> , 2019 , 381, 1718-1727	59.2	585
121	The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. <i>Radiology</i> , 2020 , 296, 172-180	20.5	471
120	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 138-153	35.1	452
119	Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 752-62	10.2	305
118	KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. <i>The American Review of Respiratory Disease</i> , 1993 , 148, 637-42		209
117	Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, e36-e69	10.2	175
116	Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 178-85	10.2	169
115	Serological diagnosis of idiopathic pulmonary alveolar proteinosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000 , 162, 658-62	10.2	167
114	Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 194, 748-61	10.2	160
113	Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 181, 1345-54	10.2	156
112	Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 453-460	35.1	154
111	Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. <i>Chest</i> , 2010 , 138, 674-81	5.3	143
110	KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1997 , 17, 501-7	5.7	126

109	Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2015 , 45, 1382-92	13.6	124
108	Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 145-53	35.1	119
107	Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. <i>BMJ Open Respiratory Research</i> , 2017 , 4, e000212	5.6	107
106	Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002 , 166, 765-73	10.2	101
105	Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997 , 156, 109-15	10.2	98
104	Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. <i>New England Journal of Medicine</i> , 2008 , 358, 199-200	59.2	98
103	Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1337-1348	10.2	97
102	Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 171, 1142-9	10.2	90
101	The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors. <i>Respirology</i> , 2007 , 12, 523-30	3.6	81
100	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 726-737	35.1	77
99	Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 554-565	35.1	75
98	Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2014 , 108, 1023-30	4.6	69
97	Pulmonary alveolar proteinosis. <i>Clinics in Chest Medicine</i> , 2004 , 25, 593-613, viii	5.3	69
96	Morphometric analysis of insulin-like growth factor-I localization in lung tissues of patients with idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998 , 158, 1626-35	19.2	69
95	Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. <i>BMJ Open Respiratory Research</i> , 2019 , 6, e000397	5.6	66
94	Quantitative CT in chronic obstructive pulmonary disease: inspiratory and expiratory assessment. <i>American Journal of Roentgenology</i> , 2009 , 192, 267-72	5.4	62
93	Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures. <i>Orphanet Journal of Rare Diseases</i> , 2016 , 11, 115	4.2	62
92	Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. <i>Journal of Immunological Methods</i> , 2014 , 402, 57-70	2.5	60

91	Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. <i>New England Journal of Medicine</i> , 2019 , 381, 923-933	9.2	58
90	Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. <i>Vaccine</i> , 2005 , 23, 2132-5	4.1	54
89	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 199-208	10.2	53
88	Long-term follow-up high-resolution CT findings in non-specific interstitial pneumonia. <i>Thorax</i> , 2011 , 66, 61-5	7.3	52
87	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	50
86	All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. <i>Respiratory Investigation</i> , 2015 , 53, 232-41	3.4	46
85	Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy. <i>Chest</i> , 2014 , 145, 729-737	5.3	43
84	Japanese guideline for the treatment of idiopathic pulmonary fibrosis. <i>Respiratory Investigation</i> , 2018 , 56, 268-291	3.4	41
83	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022 , 205, e18-e47	10.2	38
82	Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: a retrospective cohort study. <i>BMC Pulmonary Medicine</i> , 2015 , 15, 88	3.5	35
81	DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. <i>Vaccine</i> , 2006 , 24, 1191-204	4.1	35
80	Serum neutralizing capacity of GM-CSF reflects disease severity in a patient with pulmonary alveolar proteinosis successfully treated with inhaled GM-CSF. <i>Respiratory Medicine</i> , 2004 , 98, 1227-30	4.6	35
79	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 771-779	35.1	34
78	Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. <i>Chest</i> , 2020 , 158, 646-659	5.3	33
77	Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangiomyomatosis. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 1912-1922	4.7	33
76	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 1146-1153	10.2	33
75	Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan. <i>BMC Pulmonary Medicine</i> , 2014 , 14, 37	3.5	33
74	Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. <i>Respiratory Investigation</i> , 2014 , 52, 136-43	3.4	31

73	Epidemiological and clinical features of idiopathic pulmonary alveolar proteinosis in Japan. <i>Respirology</i> , 2006 , 11 Suppl, S55-60	3.6	30
72	Mast cell basic fibroblast growth factor in silicosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000 , 161, 2026-34	10.2	28
71	Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 1110-1119	10.2	28
70	Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	26
69	Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia. <i>Respirology</i> , 2016 , 21, 1431-1437	3.6	26
68	Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS randomized trials. <i>Respirology</i> , 2017 , 22, 750-757	3.6	24
67	Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. <i>New England Journal of Medicine</i> , 2020 , 383, 1635-1644	59.2	24
66	Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. <i>European Respiratory Review</i> , 2018 , 27,	9.8	24
65	High-dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias. <i>Respirology</i> , 2017 , 22, 1363-1370	3.6	23
64	Subgroup analysis of Asian patients in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. <i>Respirology</i> , 2016 , 21, 1425-1430	3.6	22
63	CYFRA 21-1 as a disease severity marker for autoimmune pulmonary alveolar proteinosis. <i>Respirology</i> , 2014 , 19, 246-252	3.6	22
62	Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF- α antibody in mice. <i>Clinical and Developmental Immunology</i> , 2011 , 2011, 404929		20
61	Lung function outcomes in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2019 , 146, 42-48	4.6	20
60	Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	18
59	Analysis of systemic lupus erythematosus-related interstitial pneumonia: a retrospective multicentre study. <i>Scientific Reports</i> , 2019 , 9, 7355	4.9	17
58	SECRETORY EFFECTS OF VASOACTIVE INTESTINAL POLYPEPTIDE (VIP), ADRENALINE AND CARBACHOL IN ISOLATED LOBULES OF THE RAT PAROTID GLAND. <i>Biomedical Research</i> , 1982 , 3, 384-389	1.5	17
57	Pulmonary Fibrosis on High-Resolution CT of Patients With Pulmonary Alveolar Proteinosis. <i>American Journal of Roentgenology</i> , 2016 , 207, 544-51	5.4	16
56	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. <i>Radiology</i> , 2021 , 298, 550-566	20.5	15

55	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. <i>Chest</i> , 2021 , 159, 1107-1125	5.3	15
54	Reductions in pulmonary function detected in patients with lymphangioleiomyomatosis: An analysis of the Japanese National Research Project on Intractable Diseases database. <i>Respiratory Investigation</i> , 2016 , 54, 193-200	3.4	15
53	Utility of expiratory thin-section CT for fibrotic interstitial pneumonia. <i>Acta Radiologica</i> , 2014 , 55, 1050-5		14
52	Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients. <i>Respirology</i> , 2018 , 23, 331-338	3.6	13
51	Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS [®] -ON. <i>Respirology</i> , 2020 , 25, 410-416	3.6	12
50	Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias. <i>Respirology</i> , 2019 , 24, 658-666	3.6	11
49	Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. <i>PLoS ONE</i> , 2019 , 14, e0212776	3.7	11
48	MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. <i>JCI Insight</i> , 2020 , 5,	9.9	11
47	Light chain (λ) ratio of GM-CSF autoantibodies is associated with disease severity in autoimmune pulmonary alveolar proteinosis. <i>Clinical Immunology</i> , 2013 , 149, 357-64	9	9
46	Disease severity staging system for idiopathic pulmonary fibrosis in Japan. <i>Respirology</i> , 2017 , 22, 1609-1614	5.14	9
45	Classification of idiopathic interstitial pneumonias using anti-myxovirus resistance-protein 1 autoantibody. <i>Scientific Reports</i> , 2017 , 7, 43201	4.9	8
44	A Semiquantitative Computed Tomographic Grading System for Evaluating Therapeutic Response in Pulmonary Alveolar Proteinosis. <i>Annals of the American Thoracic Society</i> , 2017 , 14, 1403-1411	4.7	7
43	Influence of surface light scattering and light transmissions of intraocular lenses on visual function 15 to 20 years after surgery. <i>Journal of Cataract and Refractive Surgery</i> , 2018 , 44, 219-225	2.3	7
42	Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan. <i>ERJ Open Research</i> , 2020 , 6,	3.5	7
41	Cytomegalovirus infection during immunosuppressive therapy for diffuse parenchymal lung disease. <i>Respirology</i> , 2013 , 18, 117-24	3.6	6
40	Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study. <i>International Journal of COPD</i> , 2019 , 14, 2979-2991	3	6
39	Clinical significance of serum anti-granulocyte-macrophage colony-stimulating factor autoantibodies in patients with sarcoidosis and hypersensitivity pneumonitis. <i>Orphanet Journal of Rare Diseases</i> , 2020 , 15, 272	4.2	5
38	Validation of a new serum granulocyte-macrophage colony-stimulating factor autoantibody testing kit. <i>ERJ Open Research</i> , 2020 , 6,	3.5	4

37	High-resolution CT features distinguishing usual interstitial pneumonia pattern in chronic hypersensitivity pneumonitis from those with idiopathic pulmonary fibrosis. <i>Japanese Journal of Radiology</i> , 2020 , 38, 524-532	2.9	4
36	Tracheobronchial lesions in eosinophilic pneumonia. <i>Respiratory Investigation</i> , 2014 , 52, 21-7	3.4	4
35	Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis. <i>Nature Communications</i> , 2021 , 12, 1032	17.4	4
34	Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. <i>European Respiratory Journal</i> , 2021 ,	13.6	4
33	A mathematical model to predict protein wash out kinetics during whole-lung lavage in autoimmune pulmonary alveolar proteinosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015 , 308, L105-17	5.8	3
32	Autoimmune Pulmonary Alveolar Proteinosis Following Pulmonary Aspergillosis. <i>Internal Medicine</i> , 2015 , 54, 3177-80	1.1	3
31	Autoimmune Pulmonary Alveolar Proteinosis Complicated with Sarcoidosis: the Clinical Course and Serum Levels of Anti-granulocyte-macrophage colony-stimulating Factor Autoantibody. <i>Internal Medicine</i> , 2020 , 59, 2539-2546	1.1	3
30	Insights into pathogenesis and clinical implications in myositis-associated interstitial lung diseases. <i>Current Opinion in Pulmonary Medicine</i> , 2020 , 26, 507-517	3	3
29	Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD. <i>International Journal of COPD</i> , 2019 , 14, 2993-3002	3	3
28	Corticosteroids in acute exacerbations of idiopathic interstitial pneumonias: Time to debate - Reply. <i>Respirology</i> , 2018 , 23, 546-547	3.6	2
27	Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union. <i>Current Medical Research and Opinion</i> , 2021 , 37, 327-339	2.5	2
26	2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. <i>Respiratory Investigation</i> , 2021 , 59, 709-740	3.4	2
25	Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis.. <i>Nature Communications</i> , 2022 , 13, 1558	17.4	2
24	Lymphangiomyomatosis 2016 , 1243-1259.e12		1
23	Is corticosteroid use truly not associated with improved outcomes in AE-IPF?. <i>Respirology</i> , 2020 , 25, 659	3.6	1
22	Enhanced mast cell chymase expression in human idiopathic interstitial pneumonia. <i>International Journal of Molecular Medicine</i> , 2007 ,	4.4	1
21	Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. <i>Respirology</i> , 2021 ,	3.6	1
20	Massive atelectasis by mucoid impaction in an asthma patient during treatment with anti-interleukin-5 receptor antibody. <i>Respirology Case Reports</i> , 2020 , 8, e00599	0.9	1

19	B cell-activating factors in autoimmune pulmonary alveolar proteinosis. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 115	4.2	1
18	Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin. <i>BMJ Open Respiratory Research</i> , 2021 , 8,	5.6	1
17	Blood testing in the diagnosis of pulmonary alveolar proteinosis - AuthorsSreply. <i>Lancet Respiratory Medicine,the</i> , 2018 , 6, e55	35.1	1
16	Comorbid connective tissue diseases and autoantibodies in lymphangioleiomyomatosis: a retrospective cohort study. <i>Orphanet Journal of Rare Diseases</i> , 2018 , 13, 182	4.2	1
15	Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. <i>Respiratory Medicine</i> , 2021 , 187, 106574	4.6	1
14	Hemosiderin-Laden Macrophages in Bronchoalveolar Lavage: Predictive Role for Acute Exacerbation of Idiopathic Interstitial Pneumonias.. <i>Canadian Respiratory Journal</i> , 2021 , 2021, 4595019	2.1	0
13	Lymphoplasmacytic lymphoma involving the mediastinum and the lung, followed by amyloidosis: A surgically and genetically proven case. <i>Respiratory Medicine Case Reports</i> , 2020 , 31, 101313	1.2	0
12	Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 466	4.2	0
11	Seroradiologic prognostic evaluation of acute exacerbation in patients with idiopathic interstitial pneumonia: a retrospective observational study. <i>Journal of Thoracic Disease</i> , 2020 , 12, 4132-4147	2.6	0
10	Diagnostic yield and safety of bronchofiberscopy for pulmonary alveolar proteinosis. <i>Respiratory Investigation</i> , 2021 , 59, 757-765	3.4	0
9	Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus Carrier. <i>Internal Medicine</i> , 2019 , 58, 569-574	1.1	0
8	Drug-related pneumonitis with radiographic hypersensitivity pneumonitis pattern: Three case series. <i>Respiratory Medicine Case Reports</i> , 2021 , 34, 101498	1.2	0
7	Platelet-derived growth factor can predict survival and acute exacerbation in patients with idiopathic pulmonary fibrosis.. <i>Journal of Thoracic Disease</i> , 2022 , 14, 278-294	2.6	0
6	Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework.. <i>Advances in Therapy</i> , 2021 , 39, 1045	4.1	0
5	Characteristics and prognosis of interstitial pneumonias complicated with pneumomediastinum. <i>Respiratory Investigation</i> , 2020 , 58, 262-268	3.4	
4	Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1182-1189	2.6	
3	Lymphangioleiomyomatosis 2010 , 1496-1515		
2	Anti-Myxovirus Resistance Protein-1 Immunoglobulin A Autoantibody in Idiopathic Pulmonary Fibrosis.. <i>Canadian Respiratory Journal</i> , 2022 , 2022, 1107673	2.1	

- 1 Preventing infection after synthetic expander implantation in patients undergoing breast reconstruction. **2022**, 8, 42-45